Prostate Cancer | Norton Healthcare

Indication: Prostate Cancer

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

Sub-indication: Genitourinary Cancer

Study Type: Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Merck Sharp & Dohme CORP

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.